Difference between revisions of "Part:BBa K2549019"

(→‎Our characterization)
(→‎Our characterization)
Line 16: Line 16:
  
 
It is obvious that LaG16-2-mN1c-tTAA can be significantly activated by surface-expressed EGFP.
 
It is obvious that LaG16-2-mN1c-tTAA can be significantly activated by surface-expressed EGFP.
−
 
−
[[File:Synnotch-GV2.png|none|300px|thumb|'''Flow cytometry results of an ENABLE OR gate.''' ENABLE OR gate using tTAA and GV2 as the Amplifiers. RFI: output from the Combiner after surAg activation was divided by the value before activation. Similar to tTAA, GV2 works well as an Amplifier. The TRE3GV, URE2G promoters in the Combiner receive signals from tTAA and GV2, respectively. More details please visit http://2018.igem.org/Team:Fudan/Results and http://2018.igem.org/Team:Fudan/Measurement .]]
 
−
 
−
It is obvious that LaG16-2-mN1c-tTAA ([[Part:BBa_K2549019]]) and αCD19-mN1c-GV2 ([[Part:BBa_K2549022]]) perform well as the Receptors for ENABLE OR gate.
 
  
 
=====SynNotch receptors function well in Morsut L et al 2016=====
 
=====SynNotch receptors function well in Morsut L et al 2016=====

Revision as of 18:11, 17 October 2018


LaG16-2-mN1c-tTAA

This part is the second version of our SynNotch receptors, as original published[1]. LaG16-2 (Part:BBa_K2446058) is used as the extracellular sensor module to receive the signal input from GFP. mN1c (Part:BBa_K2549006) is served as the transmembrane core domain of SynNotch, which is evident to have a low basal expression and a high activation efficiency. tTAA (Part:BBa_K2446057) is an improved tetracycline-controlled transactivator[2], which is cleaved after SynNotch activation and drives the expression of the amplifier.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal BglII site found at 381
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal NgoMIV site found at 2580
  • 1000
    INCOMPATIBLE WITH RFC[1000]
    Illegal SapI.rc site found at 1495


Biology

Our characterization
Flow cytometry results of SynNotch activation. surAg, surface antigens, which was surface-expressed CD19 for αCD19-SynNotch or surface-expressed EGFP for LaG-SynNotch, respectively. Without surAg, the EGFP (Y axis, driven by tTAA released after SynNotch activation) was low, and it went high after adding surAg. More details please visit http://2018.igem.org/Team:Fudan/Results and http://2018.igem.org/Team:Fudan/Optimization .

It is obvious that LaG16-2-mN1c-tTAA can be significantly activated by surface-expressed EGFP.

SynNotch receptors function well in Morsut L et al 2016
Morsut L et al stated:SynNotch receptors provide extraordinary flexibility in engineering cells with customized sensing/response behaviors to user-specified extracellular cues.
Morsut L et al have shown that modularity of the synNotch platform. They stated: the input and output domains from Notch can be swapped with diverse domains. On the extracellular side, diverse recognition domains can be used (antibody based, or peptide tags are shown) and on the intracellular side, diverse effector can be used (transcriptional activators with different DNA-binding domains are shown, as well as a transcriptional repressor).

Please refer to the original article for more details.

Characterization

It works as we designed.

Flow cytometry results of SynNotch receptors. surAg, surface antigens, which represent surface-expressed CD19 or surface-expressed EGFP, respectively. A EGFP-P2A circuit is placed downstream the SynNotch, which means they are in the same open reading framework.

It is obvious that LaG16-2-mN1c-tTAA can be significantly activated by surface-expressed EGFP.

References

  1. ↑ Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. Morsut L, Roybal KT, Xiong X, ..., Thomson M, Lim WA. Cell, 2016 Feb;164(4):780-91 PMID: 26830878; DOI: 10.1016/j.cell.2016.01.012
  2. ↑ Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Urlinger S, Baron U, Thellmann M, ..., Bujard H, Hillen W. Proc Natl Acad Sci U S A, 2000 Jul;97(14):7963-8 PMID: 10859354